IO Biotech, Inc. financial data

Symbol
IOBT on Nasdaq
Location
Ole Maaloes Veh 3, Copenhagen, Denmark
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 315 % -69.2%
Debt-to-equity 66.5 % +453%
Return On Equity -282 % -302%
Return On Assets -169 % -171%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9M shares 0%
Common Stock, Shares, Outstanding 65.9M shares 0%
Entity Public Float 60.6M USD +94.9%
Common Stock, Value, Issued 66K USD 0%
Weighted Average Number of Shares Outstanding, Basic 65.9M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 65.9M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 74.4M USD +6.85%
General and Administrative Expense 24.8M USD +4.35%
Operating Income (Loss) -99.2M USD -6.21%
Nonoperating Income (Expense) -3.87M USD -163%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -103M USD -18.1%
Income Tax Expense (Benefit) 918K USD +30.6%
Net Income (Loss) Attributable to Parent -104M USD -18.2%
Earnings Per Share, Basic -1 USD/shares -25.4%
Earnings Per Share, Diluted -1 USD/shares -25.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.1M USD -72.1%
Assets, Current 39M USD -63.8%
Property, Plant and Equipment, Net 603K USD -18%
Operating Lease, Right-of-Use Asset 1.47M USD -24.1%
Other Assets, Noncurrent 1.01M USD +14.7%
Assets 42.3M USD -62%
Accounts Payable, Current 5.54M USD +10.4%
Employee-related Liabilities, Current 3.35M USD +33%
Liabilities, Current 19.9M USD +45%
Operating Lease, Liability, Noncurrent 868K USD -41%
Liabilities 40.7M USD +168%
Accumulated Other Comprehensive Income (Loss), Net of Tax -6.81M USD +29.2%
Retained Earnings (Accumulated Deficit) -408M USD -34.2%
Stockholders' Equity Attributable to Parent 1.59M USD -98.3%
Liabilities and Equity 42.3M USD -62%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.1M USD +7.46%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -28K USD -155%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.9M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 77.2M USD +33.2%
Deferred Tax Assets, Gross 77.6M USD +32.9%
Depreciation 61K USD -1.61%
Payments to Acquire Property, Plant, and Equipment 28K USD +155%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -101M USD -15.1%
Lessee, Operating Lease, Liability, to be Paid 1.75M USD -25.9%
Operating Lease, Liability, Current 768K USD +13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 470K USD -40.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 863K USD +9.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 66.7M USD +32.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 208K USD +7.77%
Additional Paid in Capital 416M USD +1.58%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 300K USD +20%
Deferred Tax Assets, Net of Valuation Allowance 415K USD -13.4%
Share-based Payment Arrangement, Expense 6.49M USD -16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%